Matthew Strobeck

Matthew Strobeck (board member) discloses dealings in 5 companies, chiefly Yield10 Bioscience, Inc., Biodesix Inc and Accelerate Diagnostics, Inc. Over a trading history stretching from 15 November 2006 to 13 February 2026, the count stands at 128 filings.

Both buying and selling appear: 41 purchases worth €11.6M, against 13 sales worth €639k. The amount is not disclosed for 7 filings. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 22 share grants and 10 option exercises. In 2026 alone, the filings show 1 purchase and no sales.

In size, the median ticket on the buying side is €136k. Clusters matter here: 17 out of 18 purchases overlapped with buying by a colleague within 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. For 10 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 40% of cases, with a median move of -15.4%. They describe history only and say nothing certain about the share price ahead.

On 13 February 2026 came the latest disclosure, an open-market purchase for €202k in QuidelOrtho Corp. Typically, a trade is published a median of 4 days after it takes place. US insiders must file a Form 4 within two business days of a trade. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.